Background The US has experienced a nationwide resurgence of pertussis since the mid-1970s, de-
Pertussis, or whooping cough, is an acute respiratory disease, caused by a bacterial infection and typically characterized by a prolonged cough [1] . Despite the availability of prophylactic vaccines since the 1930s [2] , recent epidemiological data indicate that the control of pertussis remains incomplete and problematic. Indeed, the disease continues to exact a heavy toll worldwide, with an estimated 24.1 million cases and 161 thousand deaths in 2014 in children younger than 5 yr, for the most part in lowincome countries [3] . Despite large reductions in reported cases after the start of routine vaccination with Diphtheria-Tetanus-whole-cell Pertussis (DTwP, also known as DTP) vaccines, pertussis has re-emerged in several high-income countries that maintained high vaccination coverage [4, 5] . Prominently, the US has experienced a nationwide resurgence of pertussis since the mid-1970s [6, 7] , with incidence highest in infants but increasing disproportionately in adolescents and adults [8, 9] . Most recent US estimates indicate that 15,737 individuals contracted pertussis in 2016, including 1,793 cases and 6 deaths in infants [10] . Additional control measures were implemented in response to this growing burden, which have met with mixed success (e.g., [11] , but also [12, 13] ). These di culties illustrate both the complexity of, and knowledge gaps in, our understanding of pertussis biology and epidemiology [14, 15] . Foremost among the latter are uncertainties surrounding the nature of vaccinal immunity, which make the evaluation of vaccine e cacy in the field challenging [16] .
Waning immunity following vaccination with Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccines is widely believed to be responsible for the growing burden of pertussis in the US [17, 18, 19] . These subunit vaccines, based on a subset of purified antigens of Bordetella pertussis, were developed in response to concerns over the safety of DTwP vaccines [1] . Vaccine trials demonstrated the safety and the e cacy of DTaP vaccines [20] , which progressively replaced DTwP in most high-income countries, including the US which switch to the acellular vaccines in the mid-1990s [21, 22] . However, concerns over the populationlevel impacts of these vaccines soon surfaced [18] . In a recent meta-analysis that included 2 case-control studies [23, 24] and 1 cohort study [25] in the US, McGirr et al. [26] estimated that the odds of acquiring pertussis increased 1.33[1.23-1.43]-fold each year since receipt of the last dose of DTaP. Similar results were obtained in another, more recent, case-control study [27] . These results have been interpreted as evidence for widespread and rapid waning of protection conferred by DTaP vaccines, casting doubt on the vaccine's ability to control pertussis and sparking debate on the need for other control strategies [28, 17, 18] and new vaccines [29, 30] . However, it has not been established that this is a valid interpretation. Here, we demonstrate that this interpretation is in fact invalid by showing that the observed odds ratio is more consistent with much more durable vaccinal protection.
To this end, we used an empirically validated population-based model of pertussis transmission, structured according to age and parametrized using high-quality age-specific incidence data from Massachusetts [31] .
As previously reported, this model successfully captured key features of pertussis epidemiology in the US (Fig. 1) , chiefly the resurgence from the mid-1970s (Fig. 1B) and the concomitant shift of cases to adolescents and adults (Fig. 1C) [31] . According to this model, these changes are an end-of-honeymoon e ect [32] -that is, they are the slowly manifesting but predictable consequences of incomplete historical coverage with imperfect, but nevertheless e cacious, vaccines that confer slowly waning protection and generate strong herd immunity. The underlying mechanism of this e ect is illustrated in the immunological profile presented in Fig. 1A , and further explained in the legend of Fig. 1 .
Unexpectedly, we also found that our model-based estimates of the increase in the odds of pertussis were consistent with those that have been obtained in the aforementioned case-control and cohort studies commonly interpreted as evidence for rapidly waning DTaP immunity (Fig. 3F in Ref. [31] and Refs. [23, 24, 25, 26, 27] ). To fully resolve the apparent paradox, we took advantage of the validated model, adapting it to incorporate known changes in immunization practices in the US (including the switch to DTaP [21, 22] and the introduction of booster vaccination with Tdap in adolescents [33] ) and using it to systematically compare di erent measures of DTaP e cacy. Specifically, we performed extensive simulations to contrast 3 [31] , under a US-like scenario of immunization, assuming that 95% of infants are immunized with vaccines that wane slowly on average (average waning rate, 0.011 per yr, 5% probability that immunity wanes within 5 yr). A: Variations of the fraction susceptible to pertussis infection over time (x-axis), and according to age (y-axis). The top x-axis indicates changes in immunization practices assumed in the model: 1940, start of mass vaccination with DTwP; 1967, start of booster doses in children aged 15-18 mo (4th dose) and 4-6 yr (5th dose); 1992, start of DTaP for booster doses; 1997, start of DTaP for all doses. B: Total incidence of pertussis. The vertical dashed line indicates the assumed start time of mass vaccination with DTwP. C: Incidence of cases over age (x-axis) and over time (color). Each line represents a distinct year. The 3 panels illustrate the end-of-honeymoon e ect, as follows. In the prevaccine era, cases are concentrated in young children who, upon recovery, develop longlived immunity against reinfection, resulting in strong herd immunity in older individuals. The inception of mass vaccination leads to an overall reduction in transmission in those vaccinated and in the population at large. Hence, children who were not vaccinated (or in whom vaccinal protection did not initially take) are increasingly likely to reach adulthood having avoided natural infection. Concomitantly, older cohorts, with their long-lived immunity derived from natural infection during the prevaccine era, gradually die out. The result is the gradual buildup of susceptibles visible in panel A, which leads to a gradual resurgence. See Text S1 for complete details on the model formulation, parametrization, and implementation.
The results, presented in Fig. 2A , revealed a marked association between the 3 measures of vaccine e cacy. As expected, the estimated vaccine e ectiveness increased as the degree of waning decreased, exceeding 90% when immunity waned in less than 15% within 5 yr. Counterintuitively, an equally strong, but positive, association was found between the vaccine e ectiveness and the yearly increase in the odds ratio.
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To understand this result, we show in Fig. 2B the simulated incidence rates in children aged 5 to 9 yr (i.e., 0 to 4 yr following the last DTaP vaccination), for a range of assumptions regarding DTaP e cacy. Assuming a slowly waning, highly e cacious DTaP (p 5 = 0.05, VE = 0.96), pertussis incidence was predicted to increase almost linearly over age, on average by 43% after every year since last DTaP vaccination (Fig. 2B, top panel). This result is best interpreted as a consequence of the high transmissibility of pertussis (estimated Basic Reproduction Ratio, R 0 ¥ 10 in MA [31] , see also Refs. [34, 35] ): at vaccine coverage below the critical threshold, circulation persists and the risk of disease remains relatively high in groups with high contact rates, such as schoolchildren (Fig. S2 ). In contrast, the incidence profile di ered markedly in the high-waning, low-e cacy DTaP scenario (Fig. 2B, lower panel) . Here the incidence was predicted to peak 1-3 yr after last receipt of DTaP, resulting on average in a decrease in the risk of pertussis (i.e., OR AE 1).
Under this scenario, transmissibility is so high that the pool of susceptible children-including those for whom vaccinal immunity has waned-is rapidly depleted, limiting further transmission [36] . Hence, these results demonstrate an intricate relationship between the degree of waning and the odds ratios, making their interpretation di cult and their validity as a measure of vaccine e cacy and the durability of immunity questionable.
Based on the meta-analysis estimate in Ref. [26] (OR=1.33 [1.23-1.43]), we predict that the e ectiveness of DTaP in children aged 5 to 9 yr exceeds ¥75% (Fig. 2A) . We also predict that more than 65% of children remain immune to pertussis 5 yr after the last dose of DTaP, or, equivalently, that the duration of protection exceeds approximately 12 yr. Of note, we find that the odds ratio estimates become more variable when the vaccine e ectiveness exceeds 90%, as post-vaccine cases become increasingly rare and their dynamics increasingly stochastic. We propose that this finding might qualitatively explain the large estimation uncertainty found in some empirical studies [24, 25, 26] , although we acknowledge other potential sources of uncertainty not incorporated into our model. To further quantify the predicted e cacy of DTaP, we also calculated the vaccine impact, a population-level measure of the overall reduction in transmission caused by vaccination [37, 38] . We found comparable results based on this measure, with empirical estimates of odds ratios more consistent with a vaccine impact exceeding about 50% (Fig. S4) . We also found these results to be robust to alternative assumptions regarding the level of vaccine coverage, the simulation protocol, and the inclusion of demographic trends (Figs. S7-S9) . Critically, these results were also insensitive to the assumed e cacy of Tdap in teenagers (Fig. S6) . Altogether, we conclude from these experiments that, in stark opposition to recent claims [17, 18] , recent epidemiological data in the US are actually more consistent with e cacious DTaP vaccines that confer long-term protection, reduce overall transmission, and induce herd immunity. It would be a mistake to conclude, however, that routine vaccination with DTaP alone will be su cient to eradicate the disease [31] . With serological correlates of vaccinal protection still obscure [29] , the e cacy of pertussis vaccines has been regularly debated [16] . A major point of contention remains the ability of pertussis vaccines to prevent transmission, in addition to disease [39, 40, 41, 42] . Regarding DTwP vaccines, a large body of evidence (reviewed in Ref. [15] ) has shown that they can successfully reduce transmission. In contrast, there is a growing consensus that DTaP vaccines do not reduce transmission, and therefore might be inadequate to control pertussis [17, 18] . This view is partly based on evidence that DTaP generates an immune response di erent from that of DTwP or natural infection [43] , though the immunological mechanisms of vaccinal protection remain incompletely understood. Furthermore, experimental studies in animal models have suggested that vaccination with DTaP prevents symptomatic disease, but not transmissible infection [44, 41] . We have previously argued that such results cannot be straightforwardly extrapolated to human populations inasmuch as they are inconsistent with the clear-cut signatures of herd immunity following DTaP vaccination observed 7 in several countries [42, 15] The present findings entirely confirm this view, as they point to e cacious DTaP vaccines that confer an admittedly imperfect, but slowly waning immunity.
Our results have policy implications. First, the rationale behind future control strategies should incorporate the fact that, despite widespread belief, DTaP vaccines are actually e cacious and able to cause indirect e ects via herd immunity. Second, we propose that control objectives should take into account the epidemiological dynamics of pertussis, in particular its high transmissibility. Indeed, our results suggest that a relatively high burden of pertussis-including periodic outbreaks in school-aged children-may be the norm, even with e cacious but imperfect vaccines. In view of the high transmissibility of pertussis, current DTaP vaccines are likely insu cient to eradicate the disease on their own, but they nevertheless remain an important part of e ective control strategies. Empirically validated models of pertussis transmission, such as those presented here, will prove useful to define achievable control objectives, assess the impact of current control measures, and predict the e ect of new control strategies. Finally, our results emphasize the complexity of pertussis epidemiology and the fact that seemingly intuitive measures of vaccine e cacy can be misleading in the face of this complexity.
